Somatrogon-ghla
Brand names: Ngenla · Active ingredient: Somatrogon
In short: NGENLA is indicated for the treatment of pediatric patients aged 3 years and older who have growth failure due to an inadequate secretion of endogenous growth hormone.
What is Somatrogon-ghla used for?
NGENLA is indicated for the treatment of pediatric patients aged 3 years and older who have growth failure due to an inadequate secretion of endogenous growth hormone.
Somatrogon-ghla dosage
•NGENLA treatment should be supervised by a healthcare provider who is experienced in the diagnosis and management of pediatric patients aged 3 years and older with growth failure due to growth hormone deficiency (GHD) .
•Refer patient to the Instructions for Use for complete administration instructions.
•Administer NGENLA by subcutaneous injection, once weekly, on the same day each week, at any time of the day in the abdomen, thighs, buttocks, or upper arms. Rotate the injection site weekly.
•Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If flakes, particles or discoloration are observed, do not use the pen. Do not shake; shaking can damage the product.
•Prefilled pens deliver somatrogon-ghla in 0.2 mg or 0.5 mg increments.
•Perform fundoscopic examination before initiating treatment with NGENLA to exclude preexisting papilledema. If papilledema is identified, evaluate the etiology and treat the underlying cause before initiating treatment with NGENLA .
•Recommended dosage of NGENLA is 0.66 mg/kg based on actual body weight administered once weekly by subcutaneous (SC) injection.
•Individualize dosage for each patient based on the growth response.
•The day of weekly administration can be changed if necessary as long as the time between 2 doses is at least 3 days. After selecting a new dosing day, the once weekly dosing should be continued.
•When switching from daily growth hormone, the once-weekly NGENLA may be initiated on the day following their last daily injection.
•If more than one injection is required to deliver a complete dose, each injection should be administered at a different injection site.
•If a dose is missed, administer NGENLA as soon as possible within 3 days after the missed dose.
•If more than 3 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day.
How to take Somatrogon-ghla — instructions & advice from the label
Advise the patient and/or caregiver to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
•
Hypersensitivity Reactions
Advise patients and caregivers that serious systemic hypersensitivity reactions (anaphylaxis and angioedema) are possible and that prompt medical attention should be sought if an allergic reaction occurs .
•
Neoplasm
Advise childhood cancer survivors and caregivers that individuals treated with radiation to the head are at increased risk of secondary neoplasms and, as a precaution, need to be monitored for recurrence. Advise patients to report marked changes in skin pigmentation or changes in the appearance of preexisting nevi .
•
Glucose Intolerance/Diabetes Mellitus
Advise patients and caregivers that new onset of insulin resistance and hyperglycemia may occur and monitoring of blood glucose during treatment with NGENLA in patients with glucose intolerance or who have risk factors for diabetes, may be needed .
•
Intracranial Hypertension
Advise patients and caregivers to report to their healthcare provider any visual changes, headache, and nausea and/or vomiting . …
Warnings & precautions
Do not take this medicine if: •Acute critical illness after open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure due to the risk of increased mortality with somatropin .
•Hypersensitivity to somatrogon-ghla or any of the excipients in NGENLA .
•Closed epiphyses.
•Active malignancy due to the risk of malignancy progression .
•Active proliferative or severe non-proliferative diabetic retinopathy .
•Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea or have severe respiratory impairment due to the risk of sudden death .
Increased mortality in patients with acute critical illness due to complications following open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure has been reported with somatropin . The safety of continuing NGENLA treatment for the approved indication in patients who concurrently develop these illnesses has not been established.
Severe systemic hypersensitivity reactions including anaphylaxis and angioedema have been reported with somatropin. Inform patients and/or caregivers that such reactions are possible and that prompt medical attention should be sought if an allergic reaction occurs. NGENLA is contraindicated in patients with known hypersensitivity to somatrogon-ghla or any excipients in NGENLA .
Active Malignancy
There is an increased risk of malignancy progression with somatropin treatment in patients with active malignancy . Any preexisting malignancy should be inactive, and its treatment should be completed prior to instituting therapy with NGENLA. Discontinue NGENLA if there is evidence of recurrent malignancy. …
Somatrogon-ghla side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
•Increased mortality in patients with acute critical illness
•Severe hypersensitivity
•Increased risk of neoplasm
•Glucose intolerance and diabetes mellitus
•Intracranial hypertension
•Fluid retention
•Hypoadrenalism
•Hypothyroidism
•Slipped capital femoral epiphysis
•Progression of preexisting scoliosis
•Pancreatitis
•Lipoatrophy
•Sudden death in pediatric patients with Prader-Willi syndrome
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Safety data are derived from a safety and efficacy study in pediatric patients with GHD . The data from the 12-month main study period reflect exposure of 109 patients to NGENLA administered once weekly (0.66 mg/kg/wk) and 115 patients to somatropin administered once daily (0.034 mg/kg/day).
The mean age across the treatment groups, was 7.7 years (min 3.01, max 11.96); 40.2% of patients were >3 years to ≤7 years, 59.8% were >7 years, 71.9% of patients were male, and 28.1% were female. …
Drug interactions
Table 2 includes a list of drugs with clinically significant drug interactions when administered concomitantly with NGENLA and instructions for preventing or managing them.
Replacement Glucocorticoid Treatment
Clinical Impact: | Microsomal enzyme 11β-hydroxysteroid dehydrogenase type 1 (11βHSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. Growth hormone inhibits 11βHSD-1. Consequently, individuals with untreated GH deficiency have relative increases in 11βHSD-1 and serum cortisol. Initiation of NGENLA may result in inhibition of 11βHSD-1 and reduced serum cortisol concentrations.
Intervention: | Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of NGENLA .
Examples: | Cortisone acetate and prednisone may be affected more than others because conversion of these drugs to their biologically active metabolites is dependent on the activity of 11βHSD-1.
Supraphysiologic Glucocorticoid Treatment
Clinical Impact: | Supraphysiologic glucocorticoid treatment may attenuate the growth-promoting effects of NGENLA in pediatric patients. …
About this medicine
Somatrogon-ghla, a human growth hormone analog, is a fusion protein produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. It is comprised of the amino acid sequence of human growth hormone (hGH) with one copy of the C-terminal peptide (CTP) from the beta chain of human chorionic gonadotropin (hCG) at the N-terminus and 2 copies of CTP (in tandem) at the C-terminus. Somatrogon-ghla has an approximate molecular weight of 40 KDa.
NGENLA (somatrogon-ghla) injection is a sterile, clear and colorless to slightly light yellow solution for subcutaneous use supplied in a 24 mg/1.2 mL (20 mg/mL) or 60 mg/1.2 mL (50 mg/mL) single-patient-use prefilled pen.
Each 1.2 mL of solution contains either 24 mg or 60 mg of somatrogon-ghla, and the inactive ingredients citric acid monohydrate (0.3 mg), histidine (1.9 mg), metacresol (4 mg, as a preservative), poloxamer 188 (2 mg), sodium chloride (10 mg) and sodium citrate (2.8 mg) in water for injection. NGENLA has a pH of approximately 6.6. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 06dce529-b741-4a1b-8842-3ad77be6e308. Read the full official label on DailyMed.